Suppr超能文献

因子 V 东得克萨斯变异导致三代家系出血。

Factor V east Texas variant causes bleeding in a three-generation family.

机构信息

Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.

Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, USA.

出版信息

J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7.

Abstract

BACKGROUND

The factor V east Texas bleeding disorder (FVETBD) is caused by increased plasma tissue factor pathway inhibitor-α (TFPIα) concentration. The underlying cause is a variant in F5 causing alternative splicing within exon 13 and producing FV-short, which tightly binds the C-terminus of TFPIα, prolonging its circulatory half-life.

OBJECTIVES

To diagnose a family presenting with variable bleeding and laboratory phenotypes.

PATIENTS/METHODS: Samples were obtained from 17 family members for F5 exon 13 sequencing. Plasma/platelet TFPI and platelet FV were measured by ELISA and/or western blot. Plasma thrombin generation potential was evaluated using calibrated automated thrombography.

RESULTS

The FVET variant was identified in all family members with bleeding symptoms and associated with elevated plasma TFPIα (4.5- to 13.4-fold) and total TFPI (2- to 3-fold). However, TFPIα and FV-short were not elevated in platelets. TF-initiated thrombin generation in patient plasma was diminished but was restored by a monoclonal anti-TFPI antibody or factor VIIa. TFPIα localized within vascular extracellular matrix in an oral lesion biopsy from an affected family member.

CONCLUSIONS

Factor V east Texas bleeding disorder was diagnosed in an extended family. The variant was autosomal dominant and highly penetrant. Elevated plasma TFPIα, rather than platelet TFPIα, was likely the primary cause of bleeding. Plasma FV-short did not deplete TFPIα from extracellular matrix. In vitro thrombin generation was restored with an anti-TFPI antibody or factor VIIa suggesting effective therapies may be available. Increased awareness of, and testing for, bleeding disorders associated with F5 exon 13 variants and elevated plasma TFPI are needed.

摘要

背景

因子 V 东得克萨斯州出血障碍(FVETBD)是由血浆组织因子途径抑制剂-α(TFPIα)浓度升高引起的。其根本原因是 F5 中的变体导致内含子 13 中的选择性剪接,并产生 FV-short,其紧密结合 TFPIα 的 C 末端,延长其循环半衰期。

目的

诊断一个具有不同出血和实验室表型的家族。

患者/方法:从 17 名家族成员中获取 F5 外显子 13 测序样本。通过 ELISA 和/或 Western blot 测量血浆/血小板 TFPI 和血小板 FV。使用校准自动血栓生成术评估血浆凝血酶生成潜力。

结果

在所有有出血症状的家族成员中均发现了 FVET 变体,与血浆 TFPIα(4.5-13.4 倍)和总 TFPI(2-3 倍)升高有关。然而,血小板中 TFPIα 和 FV-short 没有升高。患者血浆中 TF 引发的凝血酶生成减少,但通过单克隆抗 TFPI 抗体或因子 VIIa 恢复。TFPIα 定位于受影响家族成员口腔病变活检中的血管细胞外基质中。

结论

在一个大家庭中诊断出因子 V 东得克萨斯州出血障碍。该变体是常染色体显性遗传且高度外显。升高的血浆 TFPIα,而不是血小板 TFPIα,可能是出血的主要原因。血浆 FV-short 并未从细胞外基质中耗尽 TFPIα。体外凝血酶生成用抗 TFPI 抗体或因子 VIIa 恢复,表明可能有有效的治疗方法。需要提高对与 F5 外显子 13 变体和升高的血浆 TFPI 相关的出血性疾病的认识和检测。

相似文献

1
Factor V east Texas variant causes bleeding in a three-generation family.
J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7.
2
Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.
J Clin Invest. 2013 Sep;123(9):3777-87. doi: 10.1172/JCI69091. Epub 2013 Aug 27.
3
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
Thromb Haemost. 2020 Jan;120(1):55-64. doi: 10.1055/s-0039-1700516. Epub 2019 Nov 8.
4
F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.
J Thromb Haemost. 2021 Jul;19(7):1653-1665. doi: 10.1111/jth.15314. Epub 2021 May 20.
6
Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
Thromb Haemost. 2018 Jul;118(7):1194-1202. doi: 10.1055/s-0038-1656549. Epub 2018 Jun 4.
7
Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
J Thromb Haemost. 2015 Jan;13(1):92-100. doi: 10.1111/jth.12766. Epub 2014 Nov 29.
8
Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.
J Clin Invest. 2013 Sep;123(9):3710-2. doi: 10.1172/JCI71220. Epub 2013 Aug 27.
9
Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency.
Blood Adv. 2021 Jan 26;5(2):391-398. doi: 10.1182/bloodadvances.2020003464.
10
The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg cleavage site.
J Thromb Haemost. 2017 Jan;15(1):140-149. doi: 10.1111/jth.13559. Epub 2016 Dec 3.

引用本文的文献

1
Placental Vascular Defects and Embryonic Lethality Triggered by TFPIα Deficiency in Factor V Leiden Mice.
Arterioscler Thromb Vasc Biol. 2025 Jul;45(7):1266-1276. doi: 10.1161/ATVBAHA.125.322650. Epub 2025 May 22.
3
Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives.
Res Pract Thromb Haemost. 2024 Nov 13;8(8):102625. doi: 10.1016/j.rpth.2024.102625. eCollection 2024 Nov.
4
Factor V variants in bleeding and thrombosis.
Res Pract Thromb Haemost. 2024 Jan 26;8(1):102330. doi: 10.1016/j.rpth.2024.102330. eCollection 2024 Jan.
5
Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice.
J Thromb Haemost. 2023 Mar;21(3):639-651. doi: 10.1016/j.jtha.2022.11.034. Epub 2022 Dec 22.
6
Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.
J Thromb Haemost. 2023 Mar;21(3):467-479. doi: 10.1016/j.jtha.2022.10.005. Epub 2022 Dec 22.
7
Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
J Thromb Haemost. 2022 Jun;20(6):1290-1300. doi: 10.1111/jth.15697. Epub 2022 Mar 27.

本文引用的文献

1
Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix.
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):1942-1955. doi: 10.1161/ATVBAHA.120.315728. Epub 2021 Apr 8.
2
F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.
J Thromb Haemost. 2021 Jul;19(7):1653-1665. doi: 10.1111/jth.15314. Epub 2021 May 20.
4
Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
J Biol Chem. 2021 Jan-Jun;296:100234. doi: 10.1074/jbc.RA120.016341. Epub 2021 Jan 7.
5
MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia.
Res Pract Thromb Haemost. 2020 Oct 22;4(8):1301-1312. doi: 10.1002/rth2.12438. eCollection 2020 Nov.
6
Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.
Haemophilia. 2019 Nov;25(6):1083-1091. doi: 10.1111/hae.13860. Epub 2019 Oct 14.
8
Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.
Thromb Haemost. 2018 Sep;118(9):1545-1555. doi: 10.1055/s-0038-1667198. Epub 2018 Aug 7.
10
Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S.
Res Pract Thromb Haemost. 2018 Jan;2(1):93-104. doi: 10.1002/rth2.12058. Epub 2017 Dec 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验